Bioorthogonal Glycoprotein Sequencing via Alkynyl Sugar Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity of glycan structures and their dynamic regulation pose significant challenges in deciphering their activities and roles in cellular function and dysfunction, particularly in understanding aberrant glycosylation associated with diseases like cancer, due to limitations in isolating homogenous glycans and determining saccharide composition and modification sites.
Innovation Solution
The method involves metabolic oligosaccharide engineering (MOE) using alkynyl-derivatized sugar analogs that are incorporated into cellular glycans, allowing for specific labeling and visualization through Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) probes, enabling the capture and analysis of labeled glycoproteins to identify peptide fragments and determine glycosylation sites using mass spectrometry-based proteomics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to isolate and analyze glycans, then the complexity of glycan structures can be studied, but the ability to isolate homogenous glycans and determine saccharide composition and modification sites is limited
Solution Approach 1:
The patent uses chemical probes containing bioorthogonal functional groups (azides, alkynes) as intermediaries to label glycans. These probes selectively bind to glycan structures through metabolic oligosaccharide engineering, enabling precise identification of saccharide composition and modification sites without being hindered by the overall complexity of glycan structures. The probes act as mediators that translate structural complexity into detectable signals.
Solution Approach 2:
The patent employs mass spectrometry to detect changes in mass parameters of glycans after probe labeling. By measuring mass shifts and fragmentation patterns, the method precisely determines saccharide composition and modification sites. The parameter change approach transforms the challenge of structural complexity into a measurable mass difference that can be precisely quantified.
2Reliability
If metabolic oligosaccharide engineering with alkynyl-derivatized sugar analogs is used, then specific labeling and visualization of glycans is enabled, but the process requires Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition which adds procedural steps
Solution Approach 1:
The patent utilizes the cell's own metabolic pathways to incorporate alkynyl-derivatized sugar analogs into glycans. The metabolic oligosaccharide engineering approach allows the biological system to perform the labeling function autonomously, reducing the need for external intervention. The cell's glycosylation machinery automatically incorporates the modified sugars into glycans during normal biosynthesis.
Solution Approach 2:
The Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition reaction changes the chemical state of the glycans by forming triazole linkages. This parameter change (chemical transformation) enables specific and stable labeling of glycans with detectable probes, ensuring reliable visualization while the catalytic nature of Cu(I) minimizes the amount of reagent needed.
3Measurement precision
If mass spectrometry-based proteomics is used to identify peptide fragments and determine glycosylation sites, then precise glycosylation mapping is achieved, but the analysis of complex glycoproteins requires sophisticated instrumentation and methods
Solution Approach 1:
The patent employs proteolytic digestion to segment glycoproteins into smaller peptide fragments. This segmentation simplifies the analysis by breaking down complex glycoproteins into manageable pieces that can be individually analyzed by mass spectrometry. The peptide fragments retain the glycosylation sites, allowing precise mapping while reducing the overall complexity of the sample.
Solution Approach 2:
The patent replaces traditional mechanical separation and identification methods with mass spectrometry-based detection. Instead of using complex mechanical systems for separating and identifying glycosylated peptides, the method uses mass spectral analysis to directly detect and characterize glycopeptides based on their mass-to-charge ratio and fragmentation patterns, substituting mechanical complexity with analytical precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the precise labeling and analysis of glycans, facilitating the identification of glycosylation sites and patterns, particularly in cancer cells, providing insights into aberrant glycosylation and potential biomarkers, and enabling the study of glycan dynamics and localization.
Implementation Method 1
The method involves metabolic oligosaccharide engineering (MOE) using alkynyl-derivatized sugar analogs that are incorporated into cellular glycans
Implementation Method 2
allowing for specific labeling and visualization through Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) probes
Implementation Method 3
enabling the capture and analysis of labeled glycoproteins to identify peptide fragments and determine glycosylation sites using mass spectrometry-based proteomics
Data Source
AI summary
The present disclosure relates to tailored glycoproteomic methods, and more particularly to methods for the sequencing, mapping and identification of cellular glycoproteins using saccharide-selective bioorthogonal probes. A method is disclosed for saccharide-selective glycoprotein identification (ID) and glycan mapping (GIDmap) that generates glycoproteins tailored with bioorthogonally tagged alkynyl saccharides that can be selectively isolated, allowing for glycoprotein ID and glycan mapping via mass spectromic proteomics, including liquid chromatography-tandmen mass spectroscopy (LC-MS2). LC-MS2 may be used to identify cellular glycans, and more specifically cancer-related glycoproteins.